Agilent Technologies, Inc. (NYSE:A) Director Boon Hwee Koh sold 4,500 shares of the firm’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $63.63, for a total value of $286,335.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Agilent Technologies, Inc. (A) opened at 64.38 on Friday. Agilent Technologies, Inc. has a 12 month low of $42.92 and a 12 month high of $65.18. The company has a market cap of $20.73 billion, a PE ratio of 33.20 and a beta of 1.30. The stock’s 50 day moving average is $61.25 and its 200 day moving average is $57.11.

Agilent Technologies (NYSE:A) last posted its earnings results on Tuesday, August 15th. The medical research company reported $0.59 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.52 by $0.07. The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Agilent Technologies had a net margin of 14.36% and a return on equity of 16.95%. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.49 earnings per share. Equities analysts predict that Agilent Technologies, Inc. will post $2.32 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://theolympiareport.com/2017/09/02/boon-hwee-koh-sells-4500-shares-of-agilent-technologies-inc-a-stock.html.

A has been the subject of several recent analyst reports. Barclays PLC restated a “buy” rating and set a $67.00 target price on shares of Agilent Technologies in a research note on Wednesday, July 19th. Deutsche Bank AG restated a “buy” rating and set a $66.00 target price on shares of Agilent Technologies in a research note on Thursday, June 22nd. BidaskClub downgraded Agilent Technologies from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. BTIG Research raised their target price on Agilent Technologies from $57.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, May 24th. Finally, Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $63.00 target price for the company in a research note on Tuesday, May 16th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $63.18.

A number of hedge funds have recently bought and sold shares of A. Advisor Group Inc. boosted its stake in Agilent Technologies by 0.3% in the second quarter. Advisor Group Inc. now owns 3,959 shares of the medical research company’s stock worth $235,000 after buying an additional 10 shares during the last quarter. Bronfman E.L. Rothschild L.P. boosted its stake in Agilent Technologies by 0.8% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,658 shares of the medical research company’s stock worth $276,000 after buying an additional 35 shares during the last quarter. Veritable L.P. boosted its stake in Agilent Technologies by 0.4% in the second quarter. Veritable L.P. now owns 10,896 shares of the medical research company’s stock worth $646,000 after buying an additional 40 shares during the last quarter. Park National Corp OH boosted its stake in Agilent Technologies by 1.1% in the second quarter. Park National Corp OH now owns 4,077 shares of the medical research company’s stock worth $242,000 after buying an additional 43 shares during the last quarter. Finally, Trust Co. of Vermont boosted its stake in Agilent Technologies by 1.8% in the second quarter. Trust Co. of Vermont now owns 2,793 shares of the medical research company’s stock worth $166,000 after buying an additional 50 shares during the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Insider Buying and Selling by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.